The information collection updates the
standards for FDA acceptance of data from clinical investigations
conducted outside the United States and helps ensure the protection
of human subjects and the quality and integrity of data obtained
from these investigations. We are also amending the investigational
device exemption (IDE) and premarket notification (510(k))
regulations to address the requirements for FDA acceptance of data
from clinical investigations conducted inside the United States.
The amendments are intended to provide consistency in FDA
requirements for acceptance of clinical data, whatever the
application or submission type. The information collection includes
additional maintenance, retention, and submission of documents
indicating (1) clinical investigations conducted outside the United
States and used to support IDE or device marketing applications or
submissions are conducted in accordance with good clinical practice
(GCP), and (2) availability of data for FDA inspection, if deemed
necessary. The information allows reviewers to assess the
appropriateness and adequacy of the clinical investigation design,
data collection plans, conduct, and performance, and helps to
protect human subjects participating in medical device clinical
investigations.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.